睾酮对轻度阿尔茨海默病男性患者和健康老年男性认知功能和情绪的影响  

Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men

作　　者：Masterman D.A. Mulnard R. 郭俊 

机构地区：[1]UCLA Alzheimer's Disease Center, 710 Westwood Plaza, Los Angeles, CA 90095-1769, United States

出　　处：《世界核心医学期刊文摘（神经病学分册）》2006年第6期10-11,共2页Digest of the World Core Medical Journals:Clinical Neurology

摘　　要：Background: There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD). Objective: To evaluate the effects of testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild AD and healthy elderly men. Design: Twenty-four-week, randomized, doubleblind, placebo-cont -rolled, parallel-group study. Setting : Memory disorders clinics as well as general neurology and medicine clinics from University of California medical centers at Los Angeles, San Francisco, and Irvine. Patients or Other Participants: Sixteen male patients with AD and 22 healthy male control subjects. Healthy elderly control men were recruited from the community through advertisements as well as through the university-based clinics. Intervention: Testosterone and placebo, in the form of hydroalcoholic gel (75 mg), were applied daily to the skin of the participants. Main Outcome Measures: Instruments assessing cognitive functioning (Alzheimer’s Disease Assessment Scale-Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation, Developmental Test of Visual-Motor Integration), neuropsychiatric symptoms (Neuropsychiatric Inventory), global functioning (Clinician’s Interview-Based Impression of Change), and quality of life (Quality of Life-Alzheimer Disease Scale). Results: For the patients with AD, the testosteronetreated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale (P=.01). No significant treatment group differences were detected in the cognitive scores at end of study, although numerically greater improvement or less decline on measures of visuospatial functions was demonstrated with testosterone treatment compared with placebo. In the healthy control group, a nonsignificant trend toward greater improvement in self-rated quality of life was observed in the testosterone-treated group (P=.09) compared with placBackground： There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease （AD） . Objective： To evaluate the effects of testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild AD and healthy elderly men. Design： Twenty-four-week, randomized, doubleblind, placebo-controlled, parallel-group study. Setting： Memory disorders clinics as well as general neurology and medicine clinics from University of California medical centers at Los Angeles, San Francisco, and Irvine. Patients or Other Participants： Sixteen male patients with AD and 22 healthy male control subjects. Healthy elderly control men were recruited from the community through advertisements as well as through the university-based clinics. Intervention： Testosterone and placebo, in the form of hydroalcoholic gel （75 mg）, were applied daily to the skin of the participants. Main Outcome Measures： Instruments assessing cognitive functioning （Alzheimer＇s Disease Assessment Scale-Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation, Developmental Test of Visual-Motor Integration）, neuropsychiatric symptoms （Neuropsychiatric Inventory）, global functioning （Clinician＇s Interview-Based Impression of Change）, and quality of life （Quality of Life-Alzheimer Disease Scale） . Results： For the patients with AD, the testosteronetreated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale （P =. 01 ）. No significant treatment group differences were detected in the cognitive scores at end of study, although numerically greater improvement or less decline on measures of visuospatial functions was demonstrated with testosterone treatment compared with placebo. In the healthy control group, a nonsignificant trend toward greater improvement in self-rated quality of life was ob

关 键 词：轻度阿尔茨海默病 睾酮替代治疗 健康老年男性 认知功能 男性患者 生活质量量表 神经精神症状 大学医学中心 安慰剂对照 加利福尼亚 

分 类 号：R749.16[医药卫生—神经病学与精神病学] R588[医药卫生—临床医学]